H.C. Wainwright analyst Yi Chen lowered the firm’s price target on Vaccitech to $15 from $20 and keeps a Buy rating on the shares post the Q4 results. The firm says VTP-200 demonstrated favorable tolerability and immunogenicity.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on VACC:
- Vaccitech price target lowered to $7 from $23 at Barclays
- Vaccitech reports 2022 EPS 14c vs. ($1.96) last year
- Vaccitech Reports Full-Year 2022 Financial Results and an Update on Corporate Developments
- Vaccitech announces interim data from Phase 1b/2 trial of VTP-200
- Vaccitech appoints Pelletier as Chief Scientific Officer
